Application of lithium alginate in preparation of medicine for preventing and / or treating inflammatory bowel disease
Through multi-step treatment of lithium alginate, a product with high lithium content was prepared for the treatment of inflammatory bowel disease, significantly alleviating the symptoms of inflammatory bowel disease, and regulating the intestinal flora, solving the existing treatment methods for the intestinal tract. The problems of poor mucosal damage and bacterial flora regulation have achieved better therapeutic effects.
Patent Information
- Application Number
- CN202411031686.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-07-30
AI Technical Summary
The existing treatment methods for inflammatory bowel disease are difficult to effectively alleviate symptoms such as weight loss, bloody stools and shortened colon length, and are poorly regulated intestinal flora, resulting in damage to the intestinal mucosa and an increase in the disease activity index.
Lithium alginate was used, and heated in a strong acid solution of 0.1 mol/L~1 mol/L, and then redissolved with a lithium-containing alkali solution, and then separated and washed through multiple steps of solid-liquid separation and washing. Finally, MWCO was used as The ultrafiltration membrane of 1000 Da~5000 Da was purified, and the obtained product contained 2.5%~3.8% lithium, which was used for oral treatment of inflammatory bowel disease.
Significantly alleviate symptoms of weight loss, bloody stool and shortened colon length, reduce disease activity index, protect and repair intestinal barriers, regulate intestinal flora, reverse the increase in harmful bacterial abundance, increase beneficial bacterial abundance, significantly better than traditional drugs Such as lithium carbonate and 5-aminosalicylic acid.
Smart Images

Figure CN119033808A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and in particular relates to the application of lithium alginate in the preparation of medicines for preventing and / or treating inflammatory bowel disease. Background Art
[0002] Inflammatory bowel disease (IBD) is a typical intestinal inflammatory disease. Since the first case of ulcerative colitis (UC) was reported in 1859, the incidence of IBD has been rising year by year. In 2015, the incidence of IBD in developed Western countries reached 0.5% of the total population. Studies have shown that the incidence of IBD is closely related to the process of industrialization. The pathogenesis of IBD is complex. It is currently believed that environmental factors act on genetically susceptible people, and with the participation of intestinal flora, intestinal natural immunity and acquired immunity that are difficult to stop, alternating between attacks and remissions, are initiated. This leads to pathological changes such as damaged intestinal mucosal barrier, prolonged ulcers, and inflammatory hyperplasia in patients. Nowadays, the treatment of IBD has developed from the initial research and development of single systemic or local anti-inflammatory treatment methods targeting inflammatory targets to the current comprehensive new stage of developing treatment methods based on anti-inflammatory related targets, intestinal flora, protection and promotion of mucosal healing and other strategies.
[0003] Alginic acid is a natural acidic polysaccharide, often derived from brown algae such as kelp, giant kelp, ascophyllum, and fucus. Alginic acid has a typical structural peculiarity. It is the only polysaccharide in nature that has a carboxyl group on each monosaccharide residue. Due to the peculiarity of its structure, alginate is often used as a template molecule to enhance its drugability through molecular degradation and / or structural modification. Studies have reported that alginate oligosaccharides obtained by molecular degradation of alginate, especially alginate oligosaccharides with a high guluronic acid content, show certain anti-UC effects, suggesting that special structural fragments of alginate have development potential in the treatment of IBD. Summary of the invention
[0004] In order to further enhance the anti-IBD performance of alginate, the present invention provides the use of lithium alginate in the preparation of a medicament for preventing and / or treating inflammatory bowel disease.
[0005] In order to achieve the above-mentioned purpose of the present invention, the present invention adopts the following technical scheme.
[0006] The present invention provides application of lithium alginate in preparing medicine for preventing and / or treating inflammatory bowel disease.
[0007] Furthermore, the dosage of the lithium alginate is 10 mg / kg / d to 100 mg / kg / d.
[0008] Furthermore, the structural formula of the lithium alginate is:
[0009]
[0010] Where R is Li + , its percentage content is 2.5%~3.8%; 0.9< <1.
[0011] Furthermore, the preparation method of lithium alginate comprises the following steps:
[0012] S1: Suspend alginic acid in 0.1 mol / L~1 mol / L strong acid solution and heat at 90℃~110℃ for 5 h~10 h;
[0013] S2: separating the solid-liquid separation of the feed liquid obtained in step S1 to obtain a precipitate, and re-dissolving the precipitate with a lithium-containing alkaline solution, and finally maintaining the pH value at 8-9;
[0014] S3: adjusting the pH of the solution obtained in step S2 to 2.80-3.00 with a strong acid solution, separating the feed liquid from the solid-liquid to obtain a precipitate, washing the obtained precipitate with a strong acid solution of pH 2.80-3.00, and separating the feed liquid from the solid-liquid to obtain a precipitate;
[0015] S4: suspending the precipitate obtained in step S3 with a strong acid solution, and finally maintaining the pH value at 1.80-2.80;
[0016] S5: reacting the solution obtained in step S4 at a temperature of 110° C. to 130° C. for 2 to 7 hours, then redissolving it with a lithium-containing alkaline solution, and finally maintaining a pH of 8 to 9;
[0017] S6: adjusting the pH of the solution obtained in step S5 to 2.80-3.00 with a strong acid solution;
[0018] S7: separating the solid-liquid separation of the feed liquid obtained in step S6 to obtain a precipitate, and re-dissolving the precipitate with a lithium-containing alkaline solution, and finally maintaining the pH value at 8-9;
[0019] S8: The solution obtained in step S7 is subjected to ultrafiltration purification using an ultrafiltration membrane with a MWCO of 1000 Da to 5000 Da to remove residual free inorganic metal salt ions, and a retentate is obtained; and then freeze-dried or spray-dried to obtain lithium alginate.
[0020] Furthermore, the strong acid solution is hydrochloric acid.
[0021] Furthermore, the lithium-containing alkaline solution is one or both of lithium hydroxide and lithium carbonate.
[0022] Furthermore, the lithium alginate can protect or repair the intestinal barrier; relieve weight loss, relieve symptoms of bloody stools, relieve symptoms of shortened colon length, reduce disease activity index, and reduce damage to colon tissue and mucosa; regulate intestinal flora, reverse the increased abundance of harmful bacteria Escherichia-Shigella and Romboutsia, and increase the intestinal abundance of norank_f__Muribaculaceae and Ileibacterium.
[0023] Furthermore, the lithium alginate is used orally.
[0024] Furthermore, the inflammatory bowel disease is colitis.
[0025] The present invention also provides a medicine for preventing and / or treating inflammatory bowel disease, wherein the medicine contains lithium alginate and a pharmaceutically acceptable salt, carrier or adjuvant.
[0026] Compared with the prior art, the present invention has the following positive effects:
[0027] (1) The lithium alginate obtained by the present invention has a carboxyl-bound lithium content of more than 2.5%, and a carboxyl-bound non-lithium metal content of less than 0.5%, achieving a high conversion rate of -COOH / Na to -COOLi in the alginate structure;
[0028] (2) The lithium alginate obtained by the present invention has a significantly better anti-enteritis effect than lithium carbonate with the same lithium ion dose, significantly better than sodium alginate with the same dose, and significantly better than the positive control drug 5-aminosalicylic acid in the DSS-induced ulcerative colitis model;
[0029] (3) The lithium alginate obtained by the present invention can significantly relieve the symptoms of weight loss and bloody stools, relieve the shortening of colon length, reduce the disease activity index, protect and repair the damage of colon tissue and mucosa, reverse the increased abundance of harmful bacteria Escherichia-Shigella and Romboutsia, and increase the intestinal abundance of norank_f__Muribaculaceae and Ileibacterium. It has broad application and development prospects in the preparation of drugs for the prevention and / or treatment of inflammatory bowel disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the description of the embodiments or the prior art are briefly introduced below.
[0031] Figure 1 is the infrared spectrum of lithium alginate;
[0032] Figure 2This is the H NMR spectrum of lithium alginate;
[0033] Figure 3 This is the high performance gel chromatography of lithium alginate;
[0034] Figure 4 This is a graph showing the changes in body weight of mice in the ulcerative colitis model;
[0035] Figure 5 This is a graph showing the analysis of colon length in mice in an ulcerative colitis model;
[0036] Figure 6 This is a comparison of the colon characteristics of mice in the ulcerative colitis model;
[0037] Figure 7 This is the disease activity index (DAI) score graph in the ulcerative colitis model;
[0038] Figure 8 This is a scoring diagram of mouse colon sections in the ulcerative colitis model;
[0039] Fig. 9 This is an H&E staining image of mouse colon sections in the ulcerative colitis model;
[0040] Fig.10 This is a comparison of the α-diversity of intestinal microorganisms in the normal control group and the positive control group in the ulcerative colitis model;
[0041] Fig.11 This is a comparison of the α-diversity of intestinal microorganisms in the lithium alginate group and the positive control group in the ulcerative colitis model;
[0042] Fig.12 This is a comparison of the α-diversity of intestinal microorganisms in the sodium alginate group and the positive control group in the ulcerative colitis model.
[0043] Fig.13 This is a comparison of the α-diversity of intestinal microorganisms in the lithium carbonate group and the positive control group in the ulcerative colitis model;
[0044] Fig.14 This is a comparison of the α-diversity of intestinal microorganisms in the 5-aminosalicylic acid group and the positive control group of mice in the ulcerative colitis model.
[0045] In the accompanying drawings, *P<0.05, **P<0.01, compared with the normal control group; #P<0.05, ##P<0.01, compared with the positive control group. DETAILED DESCRIPTION
[0046] Embodiments of the present invention are described in detail below in conjunction with specific examples. However, it will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention. In the examples, if specific conditions are not specified, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for reagents or instruments used, they are all conventional products that can be purchased commercially.
[0047] Example 1: Preparation of lithium alginate
[0048] Alginic acid was suspended in 0.5 mol / L hydrochloric acid solution and heated at 100 °C for 7h; the obtained feed liquid was separated from the solid-liquid to obtain the precipitate, and the precipitate was re-dissolved with lithium hydroxide solution, and the pH was finally maintained at 8~9; the pH of the re-dissolved solution was adjusted to 2.90 with hydrochloric acid, the feed liquid was separated from the solid-liquid to obtain the precipitate, and the precipitate was washed with a hydrochloric acid aqueous solution with a pH of 2.95, and the feed liquid was separated from the solid-liquid to obtain the precipitate. The precipitate was suspended with a hydrochloric acid solution, and the pH was finally maintained at 2.00, and the temperature was 120 °C for 4 h; after the reaction, the feed liquid was re-dissolved with lithium hydroxide solution, and the pH was finally maintained at 8~9; the obtained feed liquid was adjusted to pH 2.95 with hydrochloric acid again; the reaction liquid was separated from the solid-liquid to obtain the precipitate, and the precipitate was re-dissolved with lithium hydroxide solution, and the pH of the re-dissolved solution was finally maintained at 8~9, and ultrafiltration purification was performed using an ultrafiltration membrane with MWCO=1000 Da, and the intercepted liquid was freeze-dried to obtain lithium alginate.
[0049] Example 2: Preparation of lithium alginate
[0050] Alginic acid was suspended in 0.7 mol / L hydrochloric acid solution and heated at 100 °C for 8h; the obtained feed liquid was separated into solid-liquid and precipitate was obtained, the precipitate was redissolved with lithium hydroxide solution, and the pH was finally maintained at 8~9; the pH of the redissolved solution was adjusted to 2.90 with hydrochloric acid, the feed liquid was separated into solid-liquid and precipitate was obtained, the precipitate was washed with a hydrochloric acid aqueous solution with a pH of 2.95, and the feed liquid was separated into solid-liquid and precipitate. The precipitate was suspended in hydrochloric acid solution and the pH was finally maintained at 1.90, and the temperature was 120 °C for 4 h; after the reaction, the feed liquid was redissolved with lithium hydroxide solution and the pH was finally maintained at 8~9; the obtained feed liquid was adjusted to pH 2.95 with hydrochloric acid again; the reaction liquid was separated into solid-liquid and precipitate was obtained, the precipitate was redissolved with lithium hydroxide solution, and the pH of the redissolved solution was finally maintained at 8~9, and ultrafiltration purification was performed using an ultrafiltration membrane with MWCO=1000 Da, and the intercepted liquid was freeze-dried to obtain lithium alginate.
[0051] Example 3: Preparation of Sodium Alginate
[0052] Alginic acid was suspended in 0.5 mol / L hydrochloric acid solution and heated at 100 °C for 7h; the obtained feed liquid was separated into solid-liquid and precipitate was obtained, the precipitate was redissolved with sodium hydroxide solution, and the pH was finally maintained at 8~9; the pH of the redissolved solution was adjusted to 2.90 with hydrochloric acid, the feed liquid was separated into solid-liquid and precipitate was obtained, the precipitate was washed with a hydrochloric acid aqueous solution of pH 2.95, and the feed liquid was separated into solid-liquid and precipitate. The precipitate was suspended in hydrochloric acid solution and the pH was finally maintained at 2.00, and the temperature was 120 °C for 4 h; after the reaction, the feed liquid was redissolved with lithium hydroxide solution and the pH was finally maintained at 8~9; the obtained feed liquid was adjusted to pH 2.95 with hydrochloric acid again; the reaction liquid was separated into solid-liquid and precipitate was obtained, the precipitate was redissolved with sodium hydroxide solution, and the pH of the redissolved solution was finally maintained at 8~9, and ultrafiltration purification was performed using an ultrafiltration membrane with MWCO=1000 Da, and the intercepted liquid was freeze-dried to obtain sodium alginate.
[0053] Example 4: Physical and chemical properties and structural analysis of lithium alginate
[0054] (1) Metal element analysis
[0055] Experimental method: Weigh an appropriate amount of the sample into a polytetrafluoroethylene digestion tank and add 5 mL of nitric acid. Let it stand for a while. After the reaction is complete, seal the lid and place it in a microwave digestion instrument for digestion. Use an inductively coupled plasma emission spectrometer for metal element analysis.
[0056] Experimental results: The inductive coupling method measured that lithium alginate mainly contains lithium, and also contains potassium, calcium, sodium, and magnesium metal elements. In Preparation Example 1, the lithium content of the obtained lithium alginate is 2.96%, and the sum of the contents of other metal elements is 0.32%, as shown in Table 1. In Preparation Example 2, the lithium content of the obtained lithium alginate is 3.05%. In Preparation Example 3, the lithium content of the obtained sodium alginate is 0.001%.
[0057] Table 1 Metal element content of lithium alginate prepared in Example 1
[0058]
[0059] (2) Fourier transform infrared spectroscopy (FT-IR) analysis
[0060] Experimental method: The infrared spectrum of lithium alginate was detected by potassium bromide tablet method. Take about 1 mg of the sample, put it in an agate mortar, add about 100 mg of dry potassium bromide, grind it thoroughly, move it to the die, spread it evenly, press it, make it into a transparent sheet, and visually check it for uniformity. Scan it in an infrared spectrometer with a scanning range of 400 to 4000 cm -1 , and the experimental data were analyzed using OMNIC software.
[0061] Experimental results: The FT-IR spectrum of lithium alginate prepared in Example 1 is as follows: Figure 1 As shown. 3404.90 cm -1 It is the strong absorption peak of -OH on the sugar ring, 1029.90 cm -1 The characteristic absorption peak of pyranose ring skeleton vibration is 1421.28 cm -1 and 1616.67cm -1 COO - The symmetric stretching vibration peak and asymmetric stretching vibration peak are 812.21 cm -1 The absorption spectrum is characteristic of guluronic acid, and no absorption spectrum is observed at 820 cm -1 The characteristic absorption of mannuronic acid proves that lithium alginate is an alginate structure with guluronic acid as the main structural nucleus.
[0062] (3) H NMR spectroscopy ( 1 H-NMR) analysis
[0063] Experimental method: Take 20 mg of the test sample, dissolve it in 1 mL D2O, exchange D2O three times using the vacuum concentration method, dissolve it in 500 μL D2O, and 1 H-NMR analysis: The experimental data were analyzed using MestReNova software to calculate the M / G ratio.
[0064] Experimental results: The lithium alginate prepared in Example 1 1 H-NMR spectra, such as Figure 2 As shown. 5.28 ppm is the chemical shift of the hydrogen proton on the anomeric carbon C1 of the guluronic acid residue, 4.68 ppm is the chemical shift of the hydrogen proton on C5 of the guluronic acid residue, 4.35 ppm is the chemical shift of the hydrogen proton on C4 of the guluronic acid residue, 4.22 ppm is the chemical shift of the hydrogen proton on C3 of the guluronic acid residue, and 4.10 ppm is the chemical shift of the hydrogen proton on C2 of the guluronic acid residue. No signal peaks related to mannuronic acid residues were observed, and its G content was 99%.
[0065] (4) High performance gel chromatography analysis
[0066] Weigh an appropriate amount of the test sample, dissolve it in 0.2 mol / L sodium nitrate solution to prepare a 5 mg / mL solution, filter it through a 0.22 μm filter membrane, and set aside. Chromatographic conditions: The chromatographic column is TSKgel G3000PW XL (300 mm×7.8 mm, 7μm), the mobile phase was 0.2mol / L sodium nitrate solution, the flow rate was 0.5 mL / min, the column temperature was 35 ℃, the injection volume was 10 μL, the detector was a differential detector, and the detection time was 30 min.
[0067] Experimental results: The high performance gel chromatogram of lithium alginate prepared in Example 1 is as follows: Figure 3 The results show that the chromatographic peak of lithium alginate has good symmetry, and no other macromolecules or free inorganic salts are found.
[0068] Example 5: Therapeutic effect of lithium alginate on DSS-induced colitis in mice
[0069] (1) Animal experiments
[0070] Male SPF C57BL / 6J mice (8 weeks old) were kept at 22℃-25℃ and 12 h of light per day. The mice were given free water and food and fed adaptively for 7-10 days. The weight of the mice was observed and recorded every 2 days. The experiment started when the mice were 9 weeks old. The mice were randomly divided into 6 groups (n=10 in each group): 1) normal control group; 2) DSS model group; 3) sodium alginate (100 mg / kg / d) group; 4) lithium alginate (100 mg / kg / d) group; 5) lithium carbonate (20.35 mg / kg / d) group; 6) 5-aminosalicylic acid (300 mg / kg / d) group. The mice in each group were given sterile mouse maintenance feed, the normal control group was given free access to sterile water, and the DSS model group, sodium alginate group, lithium alginate group, lithium carbonate group, and 5-aminosalicylic acid group were given free access to sterile water containing 2.2% (wt / vol) DSS, and freshly prepared DSS sterile aqueous solution was replaced every 3 days. The drug was administered by intragastric gavage starting on day 0, with a gavage volume of 0.1 mL / 10 g·bw, and the normal control group and DSS model group were given an equal amount of PBS solution.
[0071] The body weight was recorded every day during the experiment, and the weight of the mice on day 0 was taken as the initial weight to calculate the percentage of weight change of the mice; if the weight of the DSS model group dropped to about 15% (about 7-9 days), the experiment was stopped, and the stool viscosity, weight loss and anal bleeding of the mice were recorded on the last day of the experiment. At the end of the experiment, the mice were eyeballed and blood was collected and the cervical spine was dislocated to be killed. After measuring the length of the mouse's blind colon, the appropriate length of colon was cut from the distal colon and stored in tissue fixative.
[0072] The disease activity index (DAI) was scored for each group of mice, and the scoring criteria are shown in Table 2.
[0073] Table 2 Disease Activity Index (DAI) Scoring Criteria
[0074]
[0075] (2) Histopathological analysis
[0076] The distal colon of mice was fixed in tissue fixative (4% PFA) and embedded in paraffin. The colon tissue was sectioned at 5 mm and stained with hematoxylin and eosin (H&E). The pathological sections were analyzed for colon mucosal integrity, inflammatory cell infiltration, and intestinal crypt loss, and the distal colon tissue sections were scored. Among them, normal tissue sections were scored as 0; mild increase in lamina propria lymphocytes was scored as 1; neutrophil infiltration, increase in lamina propria lymphocytes, and mild edema were scored as 2; diffuse increase in lamina propria lymphocytes with local erosion or mucosal ulceration was scored as 3; a large increase in lamina propria cells, large focal and / or multifocal mucosal ulceration was scored as 4; diffuse ulceration and loss of mucosal structure were scored as 5.
[0077] Experimental results:
[0078] After drinking sterile water containing DSS for 8 days, compared with the normal control group, the weight of the mice in the DSS-positive group decreased significantly (P < 0.001), the colon length was significantly shortened (P < 0.01), and the total score of DAI was significantly increased (P < 0.001), indicating that the acute ulcerative colitis model of mice was successfully established. Compared with the DSS-positive group, sodium alginate can alleviate the weight loss of mice to a certain extent, while lithium alginate can significantly inhibit the weight loss of mice (P < 0.01). Lithium carbonate and 5-aminosalicylic acid have no significant effect on the weight loss of mice (P > 0.05) ( Figure 4 In addition, sodium alginate (P < 0.01) and lithium alginate (P < 0.05) can significantly improve the symptoms of colon shortening caused by ulcerative colitis and maintain normal colon length, with no significant difference compared with the normal control group, while lithium carbonate and 5-aminosalicylic acid have no significant effect on the symptoms of colon shortening caused by ulcerative colitis (P > 0.05) ( Figure 5 and 6 ). Lithium alginate can reduce occult / visual bleeding in mice caused by acute ulcerative colitis and significantly improve loose stool symptoms (P < 0.01). Its therapeutic effect is better than that of sodium alginate. Lithium carbonate and 5-aminosalicylic acid have no obvious therapeutic effect ( Figure 7 ).
[0079] The results of histopathological analysis showed that lithium alginate could significantly reduce the histological score compared with the DSS-positive group (P<0.001) ( Figure 8 ), anatomical observations showed that lithium alginate intervention could significantly reduce DSS-induced colonic bleeding and edema in mice, and alleviate inflammatory cell infiltration, submucosal granulomas, and intestinal wall thickening in the colon of mice ( Fig. 9 ), which can protect and repair the damage of colon tissue and mucosa. Lithium alginate has a significant therapeutic effect on DSS-induced acute ulcerative colitis in mice, while lithium carbonate and 5-aminosalicylic acid have no obvious therapeutic effect.
[0080] (3) High-throughput sequencing and bioinformatics analysis
[0081] Metagenomic DNA of gut microbes in animal experiment 1 was extracted from cecal samples using the Qiagen QIAamp DNA Stool Mini Kit (Hilden, Germany). The 16S V3-V4 region of the 16S hypervariable gene was amplified by PCR using universal primers 338F (ACTCCTACGGGAGGAGCAG) and 806R (GGACTACHVGGGTWTCTAAT). The obtained amplicons were sequenced on the Illumina PE300 platform of Majorbio Bio-pharm. Bioinformatics analysis of 16S sequencing data was performed using the MajorbioCloud platform, including Venn diagrams, linear discriminant analysis effect size (LEfSe), and nonmetric multidimensional scaling (NMDS) score plots.
[0082] Experimental results:
[0083] At the genus level, the comparison between the normal control group and the positive control group clearly showed that the abundance of harmful bacteria increased in DSS-induced ulcerative colitis mice ( Fig.10 ), lithium alginate treatment significantly changed the abundance of 15 genera, reversed the increase in the abundance of harmful bacteria Escherichia-Shigella and Romboutsia, and increased the intestinal abundance of norank_f__Muribaculaceae and Ileibacterium ( Fig.11 ). By comparing the positive control group, lithium alginate group and sodium alginate group, lithium alginate can significantly reduce the abundance of Escherichia-Shigella, while the sodium alginate group did not show this phenomenon ( Fig.11 and 12 Although lithium carbonate and 5-aminosalicylic acid cannot significantly improve symptoms such as blood in stool, shortened intestinal length and weight loss, they can increase the abundance of beneficial bacteria such as Bacteroides at the intestinal microbial level ( Fig.13 and 14 ).
[0084] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for a person skilled in the art to modify the technical solutions described in the aforementioned embodiments, or to replace some of the technical features therein by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions claimed to be protected by the present invention.
Claims
1. Use of lithium alginate in the preparation of drugs for preventing and / or treating inflammatory bowel disease.
2. The use of lithium alginate according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The dosage of the lithium alginate is 10 mg / kg / d to 100 mg / kg / d.
3. The use of lithium alginate according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The structural formula of the lithium alginate is: , Where R is Li + , its percentage content is 2.5%~3.8%; 0.9< <1.
4. The use of lithium alginate according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The preparation method of lithium alginate comprises the following steps: S1: Suspend alginic acid in a strong acid solution and heat it at high temperature for 5 h~10 h; S2: separating the solid-liquid separation of the feed liquid obtained in step S1 to obtain a precipitate, and re-dissolving the precipitate with a lithium-containing alkaline solution, and finally maintaining the pH value at 8-9; S3: adjusting the pH of the solution obtained in step S2 to 2.80-3.00 with a strong acid solution, separating the feed liquid from the solid-liquid to obtain a precipitate, washing the obtained precipitate with a strong acid solution, and separating the feed liquid from the solid-liquid to obtain a precipitate; S4: suspending the precipitate obtained in step S3 with a strong acid solution, and finally maintaining the pH at 1.80-2.80; S5: reacting the solution obtained in step S4 at high temperature for 2 h to 7 h, then redissolving it with a lithium-containing alkaline solution, and finally maintaining the pH at 8 to 9; S6: adjusting the pH of the solution obtained in step S5 to 2.80-3.00 with a strong acid solution; S7: separating the solid-liquid separation of the feed liquid obtained in step S6 to obtain a precipitate, and re-dissolving the precipitate with a lithium-containing alkaline solution, and finally maintaining the pH value at 8-9; S8: The solution obtained in step S7 is subjected to ultrafiltration purification using an ultrafiltration membrane to remove the residual free inorganic metal salt ions, and the retentate is taken and then dried to obtain lithium alginate.
5. The use of lithium alginate according to claim 4 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The strong acid solution is hydrochloric acid, the concentration of which is 0.1 mol / L to 1 mol / L, and the pH is 2.80 to 3.
00.
6. The use of lithium alginate according to claim 4 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The lithium-containing alkaline solution is one or both of lithium hydroxide and lithium carbonate.
7. The use of lithium alginate according to claim 4 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The high temperature in steps S1 and S5 is 100° C. to 120° C.; the MWCO of the ultrafiltration membrane in step S7 is 1000 Da to 5000 Da.
8. The use of lithium alginate according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The lithium alginate can protect or repair the intestinal barrier; relieve weight loss, relieve symptoms of blood in stool, relieve symptoms of shortened colon length, reduce disease activity index, and reduce damage to colon tissue and mucosa; regulate intestinal flora, reverse the increased abundance of harmful bacteria Escherichia-Shigella and Romboutsia, and increase the intestinal abundance of norank_f__Muribaculaceae and Ileibacterium.
9. The use of lithium alginate according to claim 1 in the preparation of a medicament for preventing and / or treating inflammatory bowel disease, characterized in that: The inflammatory bowel disease is colitis.
10. A drug for preventing and / or treating inflammatory bowel disease, characterized in that: The medicine contains the lithium alginate as claimed in claim 3 and a pharmaceutically acceptable salt, carrier or adjuvant.
Citation Information
Patent Citations
Application of oligoguluronates in preparation of drugs for prevention and treatment of liver damage and various hepatitis, liver fibrosis or cirrhosis
CN103977021A
Application of alginate oligosaccharide in preparation of product for preventing and / or treating intestinal mucosa O-carbohydrate chain structure abnormity diseases caused by inflammation
CN114588171A
